Prevalence of multiple human papillomavirus infections and association with cervical lesions among outpatients in Fujian, China: A cross‐sectional study

Chen, Yusha; Li, Suyu; Zheng, Jinwen; Xue, Huifeng; Chen, Jiancui; Zheng, Xiangqin

doi:10.1002/jmv.28062

Cited by 11 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…inclusion of an expanded Hr-HPV genotype testing in our screening program allowed us to confirm that HPV-16/−18 (RR = 5.16) or HPV-9val genotypes (RR = 5.23) and multiple Hr-HPV infections (RR = 1.46) are important markers for HSIL or worse. The relevance of multiple Hr-HPV infections remains unclear 10,49. In summary, the characterization of a large population-based cervical cancer screening cohort confirmed a relatively high prevalence of Hr-HPV infection, especially among young women.Furthermore, Hr-HPV genotypes present in the nonavalent vaccine are responsible for the vast majority of cervical lesions and cancers, emphasizing the potential effectiveness of this vaccine in the strategy for cervical cancer eradication in our population.…”

mentioning

confidence: 74%

See 1 more Smart Citation

Impact of high‐risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real‐world data from regional cervical cancer screening program

Rosário

Sousa

Marinho‐Dias

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

Cervical cancer prevention is based on primary prevention with vaccines against Human Papillomavirus (HPV) and secondary prevention by screening with High‐Risk‐HPV (Hr‐HPV) detection. Since 2017, cervical cancer screening in women aged 25−60 years has been performed in Portugal using Hr‐HPV detection, followed by cytology in Hr‐HPV‐positive cases. Herein we report the prevalence of Hr‐HPV genotypes and cytological abnormalities among 462 401 women (mean age: 43.73 ± 10.79; median age: 45; range: 24−66 years) that participated in the Regional Cervical Cancer Screening Program of the Northern Region of Portugal, performed between August 2016 and December 2021. Overall, we describe a prevalence rate of 12.50% for Hr‐HPV varying from 20.76% at age 25% to 8.32% at age 64. The five most common Hr‐HPV genotypes identified were HPV‐68 (16.09%), HPV‐31 (15.30%), HPV‐51 (12.96%), HPV‐16 (11.06%), and HPV‐39 (11.01%). The prevalence of Hr‐HPV included in the nonavalent vaccine (HPV‐9valent) was 55.00% ranging from 47.78% to 59.18% across different age groups. Considering positive Hr‐HPV cases, 65.68% had a Negative for Intraepithelial Lesion or Malignancy (NILM) cytology, 20.83% atypical squamous cells of undetermined significance (ASC‐US), 8.85% Low‐Grade Squamous Intraepithelial Lesion (LSIL), 1.65% High‐Grade Squamous Intraepithelial Lesion (HSIL), 2.85% ASC‐H, 0.09% Atypical Glandular Cells, 0.02% Adenocarcinomas, and 0.02% Squamous Cell Carcinoma (SCC). Our analysis revealed that HPV‐9val genotypes were responsible for 52.13% NILM, 59.21% ASC‐US, 55.06% LSIL, 90.14% HSIL, 83.50% ASC‐H, and 100.00% SCC. Furthermore, multiple Hr‐HPV infections (risk ratio [RR] = 1.46; 95% confidence interval [CI] 1.34−1.58), HPV‐16/18 (RR = 5.16; 95% CI 4.75−5.93), or HPV‐9val genotypes (RR = 5.23; 95% CI 4.68−5.85) were associated with a significant risk of developing > HSIL (p < 0.001). To date, this is the largest study on Hr‐HPV genotyping in cervical cancer screening that includes data from a complete cycle of the screening program. Our findings suggest a high prevalence of HPV‐9valent genotypes and a significant association with an increased risk of developing > HSIL. This constitutes important data for health authorities, which may help define the future of vaccination and cervical cancer screening strategies.

show abstract

mentioning

confidence: 74%

“…The inclusion of an expanded Hr‐HPV genotype testing in our screening program allowed us to confirm that HPV‐16/−18 (RR = 5.16) or HPV‐9val genotypes (RR = 5.23) and multiple Hr‐HPV infections (RR = 1.46) are important markers for HSIL or worse. The relevance of multiple Hr‐HPV infections remains unclear 10,49 …”

Section: Discussionmentioning

confidence: 99%

Impact of high‐risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real‐world data from regional cervical cancer screening program

Rosário

Sousa

Marinho‐Dias

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…In the previous study, female patients who underwent colposcopies/conization following abnormal CC screening results were included, and it’s found that multiple HR-HPV infections do not increase the risk of HSIL+, compared to single HR-HPV infection ( 30 ). The previous study did not explore the risk of cervical lesions of different single HPV genotype, but mixed all high-risk HPV together.…”

Section: Discussionmentioning

confidence: 99%

Associations of human papillomavirus genotypes and cervical vascular abnormality in a cohort of women underwent colposcopy, a retrospective study of 6716 patients

et al. 2023

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

AimsAbnormal vessel patterns are specific signs in patients with early cervical abnormality and cervical cancer(CC) by colposcopy, but the impact of human papillomavirus (HPV) infections on abnormal vessel patterns remains unknown.MethodsA total of 6716 female patients with HPV infections or cytological abnormalities who underwent a colposcopy following abnormal CC screening results were included in the study. The final pathological diagnosis was confirmed to be the most severe pathological grade across cervical biopsy, endocervical canal curettage (ECC) and conization. Univariate and multivariate logistic regression analyses were used to investigate the association between HPV infections and abnormal vessel patterns, adjusting for age, gravidity and parity.ResultsThere were 6124 normal vascular cases by colposcopy and 592 cases with cervical vascular abnormality. The prevalence of HPV infections was 4284 (70%) in normal patients, and the prevalence of HPV infections was 479 (80%) in cervical vascular abnormality patients. HPV high-risk type 16 infection alone increased the risk of cervical heteromorphic blood vessels (aOR=3.66, 95%CI: 2.54~5.27). HPV 16 and 33 alone (other than the commonly recognized subtype of 18) or coinfection of these two genotypes could increase the risk of cervical punctate vascular and cervical vascular mosaic features and abnormal cervical blood vessels. An increased risk of abnormal cervical lesions was observed for HPV 16 and 33 alone or combined in coinfection compared to the negative group. The risk of cervical vascular abnormality was increased 10-fold by coinfection with HPV 16 and 33 (aOR=10.67, 95% CI: 4.54~25.09, P<0.001). HPV 16, 33 alone or combined in coinfection were associated with an increased risk of lesions more advanced than high-grade squamous intraepithelial lesion (HSIL) when compared to the negative group. The risk of lesions more advanced than HSIL was up to 26-fold higher in the coinfection with HPV 16 and 33 group than in the negative group (aOR=26.23, 95%CI: 11.23~61.27, P<0.001).ConclusionHPV16 and 33 are the most dangerous HPV genotypes correlated with abnormal vascular patterns. Combined HPV16 and HPV33 infection increases the risk of abnormal vascular patterns. Combined HPV16 and HPV33 infection increases the risk of developing HSIL+.

show abstract

“…Three types of HPV testing were performed: hybrid capture-2 testing (Qiagen, Hilden, Germany), which detects HPV DNA of 13 high-risk oncogenic types (i.e., HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), polymerase chain reaction-reverse dot blot (PCR-RDB) HPV genotyping (Yaneng® Limited Corporation, ShenZhen, China), which detects 18 types of hr-HPV (i.e., HPV16, 18,31,33,35,39,45,51,52,53,56,58,59, 66, 68, 73, 82, and 83) and 5 types of low-risk HPV (6, 11, 42, 43, and 81), and Aptima (Gen-Probe Inc, San Diego, CA), which detects HPV E6/E7 mRNA from 14 high-risk oncogenic types (i.e., HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68).…”

Section: Hpv Testingmentioning

confidence: 99%

Clinical Characteristics and Detection Sensitivity of Cervical Cancer Screening in Vaginal Intraepithelial Neoplasia

Chen,

Xue

et al. 2023

J Low Genit Tract Dis

Self Cite

View full text Add to dashboard Cite

Objective This study aimed to investigate the characteristics and screening history of vaginal intraepithelial neoplasia (VaIN) or vaginal cancer and compare the sensitivity of cytology and human papillomavirus (HPV) tests on the cervix against vaginal and cervical high-grade squamous intraepithelial lesion or cancer. Methods This study included patients who underwent colposcopy-directed biopsy and were diagnosed with VaIN or vaginal cancer from February 2013 to November 2022. Clinical information was obtained from the medical records of the department. Statistical analysis was performed on SPSS 26.0 (IBM Corp, Armonk, NY) using t test, chi-square, and Fisher exact tests. Results A total of 1,166 patients were included in this study. The median age of VaIN2+ patients was 50.5 years, whereas VaIN1 reported a median age of 42.1 years old, p < .001. This study reported that VaIN was significantly and positively correlated with cervical lesions (r = 0.244). The high-risk HPV (hr-HPV) detection rate was 88.2% (858/973) in VaIN and 95.2% in VaIN2+. Human papillomavirus 16 was the most prevalent HPV type in VaIN2+, which accounted for 54.9%, followed by HPV58 (19.5%), HPV52 (15.2%), HPV51 (12.2%), and HPV18 (11.0%). The sensitivity of hr-HPV and cytology tests on the cervix for detecting VaIN2+ was 94.7% and 83.4%, respectively. Both tests were not significantly different from detecting cervical intraepithelial neoplasia 2+. Conclusions Human papillomavirus 16 is the dominant HPV type in vaginal precancer lesions. Cervical cancer screening has similar sensitivity for VaIN2+ as for cervical intraepithelial neoplasia 2+, with hr-HPV testing showing higher sensitivity than cytology.

show abstract

Prevalence of multiple human papillomavirus infections and association with cervical lesions among outpatients in Fujian, China: A cross‐sectional study

Cited by 11 publications

References 36 publications

Impact of high‐risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real‐world data from regional cervical cancer screening program

Impact of high‐risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real‐world data from regional cervical cancer screening program

Associations of human papillomavirus genotypes and cervical vascular abnormality in a cohort of women underwent colposcopy, a retrospective study of 6716 patients

Clinical Characteristics and Detection Sensitivity of Cervical Cancer Screening in Vaginal Intraepithelial Neoplasia

Contact Info

Product

Resources

About